Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Merck KGaA, Pfizer's...

    Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

    Written by Ruby Khatun Khatun Published On 2017-12-01T09:30:13+05:30  |  Updated On 18 Aug 2021 3:39 PM IST

    FRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.


    Bavencio, or avelumab, which Merck is jointly developing with Pfizer, did not meet the primary goal of prolonging overall survival in patients whose cancer had returned or spread despite two prior treatment rounds, the two companies said in a statement on Tuesday.



    Bavencio this year won regulatory approvals against a rare and aggressive type of skin cancer and against bladder cancer. First trial results in lung cancer, its largest commercial opportunity, are not expected before next year.

    The drug is a late entrant to a fast-growing class of drugs called PD-L1 or PD-1 inhibitors that help the immune system attack cancer by blocking a mechanism tumors use to evade detection.


    Rival drugs Keytruda by Merck & Co, Bristol-Myers Squibb's Opdivo, Roche's Tecentriq and AstraZeneca's Imfinzi are seen as having bigger blockbuster potential by analysts.


    Shares in Merck KGaA were little changed while Pfizer stock was up 0.4 percent at 1521 GMT.


    Evercore ISI analyst Umer Raffat said initial expectations were low because Bavencio/avelumab was tested against chemotherapy and not against an ineffective placebo, as was the benchmark in earlier comparable studies involving rival drugs in the same class.


    The study "was a very high-risk trial, to begin with ... and the fact that it didn't work doesn't necessarily imply that avelumab is worse off on efficacy vs Opdivo/Keytruda etc.," he said in a note.


    "We are confident that our broad clinical development program in both monotherapy and combinations across a range of cancers will continue to bring new potential treatment options to patients," Chris Boshoff, Pfizer's head of immuno-oncology said in the statement.


    Despite the disappointment in the so-called JAVELIN Gastric 300 trial, the two companies will continue to explore Bavencio in the JAVELIN Gastric 100 trial in an earlier treatment setting.




    (Reporting by Ludwig Burger; Editing by Jane Merriman, Greg Mahlich)



    AstraZenecaAvelumabBavenciobladder cancerBristol-Myers SquibbcancerchemotherapyChris Boshofffailsgastric cancerImfinziimmune systemimmunotherapyJAVELIN Gastric 100 trialJAVELIN Gastric 300 trialKeytrudaMerckMerck KGaAOpdivoPD-1 inhibitorsPD-L1 inhibitorsPfizerRocheskin cancerTecentriqtrial
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok